<DOC>
	<DOCNO>NCT01460199</DOCNO>
	<brief_summary>This study conduct evaluate safety tolerability treatment CTP-499 non-dialysis patient associate moderate chronic kidney disease .</brief_summary>
	<brief_title>Safety &amp; Tolerability Study CTP-499 Patients With Moderate Chronic Kidney Disease</brief_title>
	<detailed_description>This study evaluate safety tolerability treatment CTP-499 start 600 milligram ( mg ) day ( QD ) 2 week follow 600 mg twice day ( BID ) 2 week non-dialysis patient associate moderate chronic kidney disease define estimate Glomerular Filtration Rate eGFR 30-59 mL/min/1.73m2</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Patient diagnosis chronic kidney disease If take antihypertensive antidiabetes medication , regimen must stable minimum 4 week Patient systolic blood pressure less equal 160 mm Hg diastolic blood pressure less equal 95 mm Hg Patient concurrent condition uncontrolled inflammatory disease , acute infection clinically unstable autoimmune , endocrine , neurological , psychiatric , retinal , cardiovascular , bronchopulmonary , hepatic , gastrointestinal musculoskeletal disorder Patient acute , active and/or current unstable renal impairment disease Patient hospitalize acute renal failure past year Patient active malignancy history neoplastic disease Patient QTc interval &gt; 450 millisecond Patient currently cytotoxic immunosuppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>